Peptides DB
Research-centric peptide and protocol reference hub

Mazdutide (IBI362) record · updated 7h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 5 studiesJump to the evidenceCompare
What is Mazdutide (IBI362) used for?

Mazdutide (IBI362) is an investigational dual GLP-1/glucagon receptor agonist studied for weight loss and type 2 diabetes, combining appetite suppression with increased energy expenditure.

How it works: GLP-1 / glucagon dual receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Mazdutide (IBI362) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 16 registered trials. It describes the research record, not a recommendation.

Identity
NameMazdutide (IBI362)
Full name—
Sequence—
ClassWeight Loss
Research levelExtensively Studied
Discovered byCurated master list · 2026
Pharmacology
MechanismGLP-1 / glucagon dual receptor agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
DurationWeekly dosing (investigational)
Extraction confidence0.60
Effect profile · 0–5
Metabolic & appetite: Healing 0.0, Muscle 0.0, Metabolic 5.0, Neuro 0.0, Sleep 0.0, Immune 0.0, Skin 1.0Metabolic & appetite — 5.0 / 5Skin & aesthetics — 1.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin0.00.05.00.00.00.01.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies5
Human / animal / cellular4 / 1 / 0
Highest trial phasePreclinical
Years covered2023–2026
Latest study14d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

5 rowsOpen in the library →
StudyTypeYearSummary depth
Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
FindingMD -11.1% body weight vs placebo at 6 mg, n=2292.
Human2026Full text read0.80
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
FindingMean difference in weight loss with tirzepatide -14.9%, 95% CI -16.0% to -13.9%, n=99,791.
Human2026Full text read0.90
Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.
FindingMyocardial glucose uptake increased from a median of 9.2×10^-3 µmol/g/min to 20×10^-3 µmol/g/min, n=8, P<0.05.
Human—Full text read0.80
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
Finding16% mean body weight reduction over 68 weeks with semaglutide.
Human—Full text read0.80
Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
FindingNot reported in abstract.
Animal2023Full text read0.70